Open AccessExtended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants
Author(s) -
Carolyne OnyangoMakumbi,
Arthur H. Owora,
Ramadhani S. Mwiru,
Anthony Mwatha,
Alicia Young,
Dhayendre Moodley,
Hoosen Coovadia,
Lynda StranixChibanda,
Karim Manji,
Yvonne Maldonado,
Paul Richardson,
P. Andrew,
Kathleen George,
Wafaie W. Fawzi,
Mary Glenn Fowler
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002145
Subject(s) - nevirapine , medicine , underweight , wasting , population , pediatrics , breastfeeding , proportional hazards model , efavirenz , hazard ratio , human immunodeficiency virus (hiv) , body mass index , immunology , overweight , environmental health , antiretroviral therapy , confidence interval , viral load
Effects of prolonged nevirapine prophylaxis exposure on growth among HIV-exposed uninfected (HEU) infants are unknown. This study examines the impact of extended nevirapine prophylaxis from 6 weeks to 6 months on the growth of HEU infants followed for 18 months and also identifies correlates of incident wasting, stunting, underweight, and low head circumference in the HPTN 046 trial.